Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1711-1720

  Halloran, Philip F ^a,b   Chang, Jessica ^a   Famulski, Konrad ^a,c   Hidalgo, Luis G ^a,c   Salazar, Israel D R ^a   Lopez, Maribel Merino ^a   Matas, Arthur ^d   Picton, Michael ^e   De Freitas, Declan ^e,f   Bromberg, Jonathan ^g   Serón, Daniel ^h   Sellarés, Joana ^h   Einecke, Gunilla ⁱ   Reeve, Jeff ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Department of Medicine Division of Nephrology and Transplant Immunology   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f BEAUMONT HOSPITAL   (Ireland)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY MEDIATED REJECTION; ARTICLE; CONTROLLED STUDY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; T CELL MEDIATED REJECTION; TREATMENT FAILURE; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; EUROPE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MALE; MOLECULAR DIAGNOSIS; MORTALITY; MULTICENTER STUDY; NEEDLE BIOPSY; NORTH AMERICA; PROCEDURES; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; T LYMPHOCYTE; TIME FACTOR; TRANSPLANTATION TOLERANCE;

ANTIBODY;

ANTIBODIES; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; EUROPE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; NORTH AMERICA; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANT RECIPIENTS; TRANSPLANTATION TOLERANCE;

EID: 84934753499     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014060588     Document Type: Article

References (46)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, Johansen K, Kasiske BL, Kutner N, Liu J, St. PeterW, Guo H, Hu Y, Kats A, Li S, Li S, Maloney J, Roberts T, Skeans M, Snyder J, Solid C, Thompson B,Weinhandt E, Xiong H, Yusuf A, Zaun D, Arko C, Chen SC, Daniels F, Ebben J, Frazier E, Johnson R, Sheets D, Wang X, Forrest B, Berrini D, Constantini E, Everson S, Eggers P, Agodoa L: US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 63[1 Suppl]: A7, 2014
2. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG: Identifying specific causes of kidney allograft loss. Am J Transplant 9: 527-535, 2009
3. Sellarés J, de Freitas DG,MengelM, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388-399, 2012
4. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 9: 2520-2531, 2009
5. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ: Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90: 68-74, 2010
6. Furness PN, Taub N, Assmann KJ, Banfi G, Cosyns JP, Dorman AM, Hill CM, Kapper SK, Waldherr R, Laurinavicius A, Marcussen N, Martins AP, Nogueira M, Regele H, Seron D, Carrera M, Sund S, Taskinen EI, Paavonen T, Tihomirova T, Rosenthal R: International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 27: 805-810, 2003
7. Reeve J, Sellarés J,MengelM, Sis B, Skene A, Hidalgo L, de Freitas DG, Famulski KS, Halloran PF: Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 13: 645-655, 2013
8. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF: Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 13: 971-983, 2013
9. Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, EineckeG, Reeve J: Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 13: 2352-2363, 2013
10. Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J: Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 13: 2865-2874, 2013
11. Furness PN, Taub N; Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project: International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. Kidney Int 60: 1998-2012, 2001
12. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MCR, David DSR, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, LiapisH, Loupy A,Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee: Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14: 272-283, 2014
13. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X: Antibody-mediated vascular rejection of kidney allografts: A populationbased study. Lancet 381: 313-319, 2013
14. Iványi B, Marcussen N, Olsen S: Tubulitis in primary vascular and glomerular renal disease. Pathol Res Pract 191: 1245-1257, 1995
15. Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM; European Vasculitis Society: Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23: 313-321, 2012
16. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS: The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49: 85-91, 1990
17. Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, Mengel M, Matas A, Halloran PF: A new diagnostic algorithm for antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 12: 1168-1179, 2012
18. Baid-Agrawal S, Farris AB 3rd, Pascual M, Mauiyyedi S, Farrell ML, Tolkoff-Rubin N, Collins AB, Frei U, Colvin RB: Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 80: 879-885, 2011
19. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, Held E, Riethmüller G, Land W, Albert E: Vascular deposition of complement-split products in kidney allografts with cellmediated rejection. Clin Exp Immunol 86: 464-470, 1991
20. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, CascalhoM, Collins AB,Demetris AJ,Drachenberg CB,Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, SalomonDR, SeronD, Sheaff M, Weening JJ: Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007
21. Halloran PF, Langone AJ, Helderman JH, Kaplan B: Assessing longterm nephron loss: Is it time to kick the CAN grading system? Am J Transplant 4: 1729-1730, 2004
22. Kao KJ, Chang KM, Hsu HC, Huang AT: Correlation of microarraybased breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. BMC Cancer 11: 143, 2011
23. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, CherbavazDB, Shak S, Page DL, SledgeGWJr.,DavidsonNE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105: 701-710, 2013
24. Hartmann S, Gerber B, Elling D, Heintze K, Reimer T: The 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast cancer. Breast Care (Basel) 7: 19-24, 2012
25. Silver N: The Signal and the Noise: Why So Many Predictions Fail-but Some Don't, 1st Ed., New York, The Penguin Press, 2012
26. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF:De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 9: 2532-2541, 2009
27. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl JMed 351: 2715-2729, 2004
28. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 Study Group: Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120: 1836-1847, 2010
29. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848-1861, 2010
30. Londoño MC, Danger R, Giral M, Soulillou JP, Sánchez-Fueyo A, Brouard S: A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant 12: 1370-1377, 2012
31. Martínez-LlordellaM, Lozano JJ, Puig-Pey I,OrlandoG, TisoneG, Lerut J, Benítez C, Pons JA, Parrilla P, Ramírez P, Bruguera M, Rimola A, Sánchez-Fueyo A: Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118: 2845-2857, 2008
32. Bohne F, Martínez-Llordella M, Lozano JJ, Miquel R, Benítez C, Londoño MC, Manzia TM, Angelico R, Swinkels DW, Tjalsma H, López M, Abraldes JG, Bonaccorsi-Riani E, Jaeckel E, Taubert R, Pirenne J, Rimola A, Tisone G, Sánchez-Fueyo A: Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation.JClinInvest 122: 368-382, 2012
33. Benítez C, LondoñoMC, Miquel R,ManziaTM, Abraldes JG, Lozano JJ, Martínez-Llordella M, López M, Angelico R, Bohne F, Sese P, Daoud F, Larcier P, Roelen DL, Claas F,Whitehouse G, Lerut J, Pirenne J, Rimola A, Tisone G, Sánchez-Fueyo A: Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 58: 1824-1835, 2013
34. Sanchez-Fueyo A: Tolerance profiles and immunosuppression. Liver Transpl 19[Suppl 2]: S44-S48, 2013
35. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, Klintmalm GB, Terasaki PI: High mean fluorescence intensity donorspecific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant 11: 1868-1876, 2011
36. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007
37. Vincenti F, Larsen C, Durrbach A,Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, HagertyD, Levy E, ZhouW,Natarajan K, Charpentier B; Belatacept Study Group: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005
38. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J; Daclizumab Triple Therapy Study Group: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl JMed 338: 161-165, 1998
39. Matas AJ, Gillingham KJ, Payne WD, Najarian JS: The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57: 857-859, 1994
40. Meier-Kriesche H-U, Ojo AO, Hanson JA, Cibrik DM, Punch JD, Leichtman AB, Kaplan B: Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 70: 1098-1100, 2000
41. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial MC, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 10: 547-557, 2010
42. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P,Massari P,Mondragon-Ramirez GA, AgarwalM, Di Russo G, Lin CS, Garg P, Larsen CP: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546, 2010
43. Mirnezami R, Nicholson J, Darzi A: Preparing for precision medicine. N Engl JMed 366: 489-491, 2012
44. Mueller TF, EineckeG, Reeve J, Sis B,MengelM, JhangriGS, Bunnag S, Cruz J, Wishart D, Meng C, Broderick G, Kaplan B, Halloran PF: Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 7: 2712-2722, 2007
45. Luo J, SchumacherM, Scherer A, Sanoudou D,Megherbi D, Davison T, Shi T, TongW, Shi L, Hong H, Zhao C, Elloumi F, Shi W, Thomas R, Lin S, Tillinghast G, Liu G, Zhou Y, Herman D, Li Y, Deng Y, Fang H, Bushel P, Woods M, Zhang J: A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J 10: 278-291, 2010
46. Scholtens D, von Heydebreck A: Statistics for Biology and Health: Bioinformatics and Computational Biology Solutions Using R and Bioconductor., XII, edited by Gentleman R, Carey VJ, HuberW, Irizarray R, Dudoit S, New York, Springer, 2005, pp 229-248